

Appendix: Tables

1.	Sales January to September 2021 and 2020.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020.....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020.....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	11

1. Sales January to September 2021 and 2020

CHF millions	Nine months ended 30 September		% change	
	2021	2020	At CER	In CHF
Pharmaceuticals Division	33,379	34,317	0	-3
United States	16,707	18,389	-5	-9
Europe	6,610	6,268	3	5
Japan	3,186	2,802	20	14
International*	6,876	6,858	2	0
Diagnostics Division	13,305	9,662	39	38
Roche Group	46,684	43,979	8	6

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020

CHF millions	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020
Pharmaceuticals Division	11,115	-4	10,215	-7	10,600	-9	11,071	4	11,708	5
United States	5,925	-5	5,258	-13	5,292	-14	5,510	0	5,905	0
Europe	2,078	2	1,930	-8	2,175	-6	2,310	15	2,125	1
Japan	894	-13	963	-5	852	-7	956	7	1,378	60
International*	2,218	-2	2,064	11	2,281	0	2,295	4	2,300	2
Diagnostics Division	3,583	18	4,129	28	4,330	55	4,712	48	4,263	18
Roche Group	14,698	1	14,344	1	14,930	3	15,783	14	15,971	8

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020

Top-selling pharmaceuticals January - September 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,721	17	2,779	11	689	37	-	-	253	50
Perjeta	2,974	4	1,079	-1	847	-3	200	-4	848	24
Actemra/RoActemra	2,690	30	1,300	44	663	14	285	12	442	29
Tecentriq	2,477	27	1,272	14	520	17	387	81	298	66
Avastin	2,390	-39	745	-48	346	-69	502	-1	797	-12
Hemlibra	2,172	42	1,317	35	440	65	260	21	155	138
Herceptin	2,061	-32	501	-55	407	-24	63	-39	1,090	-15
MabThera/Rituxan	1,968	-41	1,197	-47	203	-35	31	-34	537	-26
Kadcyla	1,460	16	613	4	508	23	94	57	245	26
Xolair	1,416	2	1,416	2	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020

New products January - September 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	196	-3	128	-5	44	-6	-	-	24	18
Perjeta	2,974	4	1,079	-1	847	-3	200	-4	848	24
Kadcyla	1,460	16	613	4	508	23	94	57	245	26
Gazyva/Gazyvaro	501	8	232	9	167	5	47	-3	55	29
Esbriet	789	-4	556	-4	202	-1	-	-	31	-25
Cotellic	35	-9	10	21	13	-20	-	-	12	-13
Alecensa	988	19	263	7	221	12	181	10	323	47
Tecentriq	2,477	27	1,272	14	520	17	387	81	298	66
Ocrevus	3,721	17	2,779	11	689	37	-	-	253	50
Hemlibra	2,172	42	1,317	35	440	65	260	21	155	138
Xofluza	-5	-	-8	-	-	-	-	-	3	69
Polivy	167	35	67	-17	63	48	29	-	8	**
Rozlytrek	35	137	23	90	5	**	5	176	2	**
Phesgo	213	**	98	**	92	-	-	-	23	-
Enspryng	69	**	15	249	1	**	52	**	1	**
Evrysdi	396	**	268	**	62	-	3	-	63	-
Gavreto***	5	-	5	-	-	-	-	-	-	-
Ronapreve	1,084	-	-	-	568	-	360	-	156	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

*** January - June 2021 sales booked by partner Blueprint Medicines

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2021 vs. YTD September 2020

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,721	17	2,779	11	689	37	-	-	253	50
Perjeta	2,974	4	1,079	-1	847	-3	200	-4	848	24
Actemra/RoActemra	2,690	30	1,300	44	663	14	285	12	442	29
Tecentriq	2,477	27	1,272	14	520	17	387	81	298	66
Avastin	2,390	-39	745	-48	346	-69	502	-1	797	-12
Hemlibra	2,172	42	1,317	35	440	65	260	21	155	138
Herceptin	2,061	-32	501	-55	407	-24	63	-39	1,090	-15
MabThera/Rituxan	1,968	-41	1,197	-47	203	-35	31	-34	537	-26
Kadcyla	1,460	16	613	4	508	23	94	57	245	26
Xolair	1,416	2	1,416	2	-	-	-	-	-	-
Ronapreve	1,084	-	-	-	568	-	360	-	156	-
Lucentis	1,017	-5	1,017	-5	-	-	-	-	-	-
Alecensa	988	19	263	7	221	12	181	10	323	47
Activase/TNKase	921	-5	879	-5	-	-	-	-	42	4
Esbriet	789	-4	556	-4	202	-1	-	-	31	-25
Gazyva	501	8	232	9	167	5	47	-3	55	29
CellCept	453	-2	35	-23	115	-5	52	-8	251	5
Pulmozyme	414	-15	262	-20	89	-13	0	-17	63	15
Evrysdi	396	**	268	**	62	-	3	-	63	-
Mircera	331	-7	-	-	41	-11	90	-17	200	-1

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020
Ocrevus	1,198	37	1,052	10	1,226	16	1,212	31	1,283	7
Perjeta	988	17	954	20	988	2	980	7	1,006	2
Actemra/RoActemra	673	27	724	29	779	22	863	12	1,048	57
Tecentriq	718	49	723	35	775	26	824	31	878	23
Avastin	1,188	-30	969	-35	863	-40	782	-40	745	-37
Hemlibra	572	57	615	45	661	33	732	58	779	37
Herceptin	879	-38	653	-43	755	-35	641	-35	665	-26
MabThera/Rituxan	1,003	-33	780	-43	705	-46	674	-34	589	-42
Kadcyla	458	33	450	26	478	17	481	21	501	11
Xolair	493	3	453	3	409	-6	478	3	529	8
Ronapreve	-	-	-	-	166	-	429	-	489	-
Lucentis	392	-5	324	-22	337	-7	328	2	352	-10
Alecensa	301	37	319	54	298	14	333	25	357	18
Activase/TNKase	314	1	316	11	304	-17	294	3	323	3
Esbriet	278	5	264	-9	256	-8	270	1	263	-5
Gazyva	162	15	160	6	155	-2	169	18	177	10
CellCept	148	-11	144	-1	154	-5	144	-3	155	3
Pulmozyme	148	-16	142	-17	139	-23	137	-13	138	-7
Evrysdi	8	-	47	-	80	-	163	-	153	*
Mircera	118	-26	101	-24	105	-13	109	-10	117	1

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020
Ocrevus	193	56	184	20	217	37	205	40	267	36
Perjeta	291	13	292	4	301	-3	277	2	269	-8
Actemra/RoActemra	186	10	215	24	239	12	217	20	207	10
Tecentriq	155	72	139	18	168	14	171	20	181	16
Avastin	286	-33	170	-61	138	-68	119	-69	89	-69
Hemlibra	115	171	112	99	136	71	156	123	148	26
Herceptin	161	-30	143	-31	146	-25	131	-25	130	-20
MabThera/Rituxan	102	-29	75	-36	69	-45	65	-21	69	-33
Kadcyla	147	39	156	34	167	24	169	29	172	16
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	166	-	317	-	85	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	68	22	71	22	74	11	74	19	73	7
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	64	-2	68	2	69	-10	68	9	65	0
Gazyva	54	26	56	15	51	-11	55	19	61	10
CellCept	39	-8	38	-10	38	-22	39	17	38	-2
Pulmozyme	31	3	34	4	30	-20	30	-7	29	-10
Evrysdi	-	-	-	-	-	-	27	-	35	-
Mircera	14	-14	13	-17	13	-23	14	-7	14	-3

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	70	-9	75	0	64	-11	68	-2	68	0
Actemra/RoActemra	86	-15	99	1	84	-2	98	15	103	25
Tecentriq	77	62	105	75	120	82	137	86	130	75
Avastin	171	-25	183	-7	161	-8	169	0	172	5
Hemlibra	76	13	86	15	79	11	87	21	94	29
Herceptin	32	-46	31	-43	22	-43	21	-37	20	-37
MabThera/Rituxan	15	-38	16	-34	10	-37	10	-34	11	-30
Kadcyla	22	7	27	41	27	54	33	57	34	59
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	-	-	360	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	58	8	67	29	55	8	63	10	63	11
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	15	-36	18	-9	14	1	17	-17	16	10
CellCept	19	-3	21	1	17	-9	18	-7	17	-7
Pulmozyme	1	40	0	-15	0	-23	0	-9	0	-18
Evrysdi	-	-	-	-	-	-	-	-	3	-
Mircera	39	-20	40	-18	29	-18	31	-15	30	-18

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020	Q3 2021	% change vs. Q3 2020
Ocrevus	66	74	70	55	95	77	72	41	86	35
Perjeta	259	52	249	135	263	23	292	34	293	16
Actemra/RoActemra	151	209	140	114	151	134	164	27	127	-14
Tecentriq	64	74	79	86	92	84	100	56	106	62
Avastin	299	-14	310	8	277	-4	251	-20	269	-11
Hemlibra	25	58	49	325	48	214	50	92	57	138
Herceptin	373	-28	284	-29	396	-16	332	-22	362	-7
MabThera/Rituxan	214	-30	190	-24	200	-23	170	-30	167	-25
Kadcyla	76	30	77	50	84	28	78	35	83	16
Xolair	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	112	-	44	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	86	141	95	**	92	44	106	59	125	40
Activase/TNKase	12	-5	14	1	13	-10	15	6	14	17
Esbriet	14	5	10	-9	14	0	14	-7	3	-73
Gazyva	15	5	15	-1	16	21	18	23	21	43
CellCept	75	-10	70	4	88	11	75	-8	88	13
Pulmozyme	17	-6	14	-7	24	3	19	40	20	12
Evrysdi	-	-	1	-	1	-	49	-	13	-
Mircera	65	-31	48	-30	63	-8	64	-8	73	13

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%